Equillium (EQ) EBIT Margin (2023 - 2024)
Equillium's (EQ) quarterly EBIT Margin came in at 106.97% in Q4 2024, down 7223.0% year-on-year from 1.5% in Q1 2024, and down 1815.8% on a QoQ basis from 5.58% in Q3 2024.
Equillium (EQ) EBIT Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has 2 years of EBIT Margin data on file, last reported at 106.97% in Q4 2024.
- On a quarterly basis, EBIT Margin fell 7223.0% year-over-year to 106.97% in Q4 2024; TTM through Sep 2025 was 554.9%, a 54015.0% decrease from a year earlier, with the FY2024 full-year figure at 20.12%, up 2012.0% from the prior year.
- EBIT Margin for Q4 2024 stood at 106.97%, down from 5.58% in the prior quarter.
- Over the last five years, EBIT Margin for EQ reached as high as 0.72% in Q2 2024 and fell as low as 106.97% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Equillium | 242.14 Mn | 242.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -106.97% |
| Sep 30, 2024 | -5.58% |
| Jun 30, 2024 | -0.72% |
| Mar 31, 2024 | -26.11% |
| Dec 31, 2023 | -34.74% |
| Sep 30, 2023 | -40.85% |
| Jun 30, 2023 | -39.36% |
| Mar 31, 2023 | -46.27% |